Two deaths with Novartis gene therapySwiss-headquarterd Novartis AG has reported two cases of fatal liver failure after treatment with the gene therapy Zolgensma. more ➔
Azenta set to acquire B Medical SystemsAzenta Inc has entered into an agreement to acquire B Medical Systems S.á r.l. and its subsidiaries for €410m. more ➔
Sartorius pays £415m for Albumedix LtdSartorius Stedim Biotech has purchased the world’s largest human albumin producer Albumedix to broaden its product portfolio in animal-free cell media and to stabilise protein drugs. more ➔
BioNtech SE expands collab with Genmab A/SAs Genmab’s Hexabody tumour antibody platform is advancing, BioNTech has secured a licence in the field of immunotherapy to co-develop antibodies on 50:50 base. more ➔
F2G to use $70m financing to advance olorofilmBritish antifungal developer F2G Ltd has announced a $70mn financing round to push development of its late-stage compound olorofilm. more ➔
Sosei announces $1.2bn R&D collaboration with AbbvieSosei Heptares and AbbVie have inked a multi-target licence option drug discovery agreement in neurology. more ➔
UK-Spanish team to optimise efficacy of microbial production processesResearchers have presented a novel method to promote biofilm formation and thus to increase efficiency of biocatalysis in biotech production. more ➔
InflaRX set to file for MAA for vilobelimabInflaRx plans to apply for Emergency Use Authorization from the US FDA in Q3/2022 for vilobelimab, the company’s treatment for critically ill COVID-19 patients. more ➔
New Amsterdam Pharma merges with Frazier Lifesciences Acquisition Corp.Through a $325m SPAC transaction with Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Holding B.V. will go public on Nasdaq. The newly formed holding company, NewAmsterdam Pharma Company … more ➔
New antibody cocktail might fight all corona variantsA nasal antibody cocktail binding to the conserved S2 stalk region of SARS-COV-2 might end the corona pandemic. more ➔
